Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Nocturia Market Size Forecast: How Large Could The Market Become By 2030?
In recent times, the nocturia market has experienced significant expansion, projecting an increase from $3.1 billion in 2025 to $3.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.0%. This historical growth trajectory has been propelled by factors such as a growing elderly demographic, a heightened occurrence of benign prostatic hyperplasia, the increasing prevalence of urinary tract infections, extensive prescription of diuretic medications, and a notable lack of early diagnostic awareness.
The market for treating nocturia is poised for substantial expansion over the coming years, projecting to reach $4.51 billion by 2030 with a compound annual growth rate (CAGR) of 7.7%. This anticipated growth trajectory is fueled by several key factors: a heightened demand for tailored treatment approaches, the increasing availability of at-home care options, escalating healthcare spending, a greater emphasis on managing sleep quality, and enhanced accessibility to urology specialists. Simultaneously, significant market trends shaping this period include an aging global population accompanied by a rise in age-associated urological conditions, a growing incidence of diabetes and metabolic ailments, elevated awareness and diagnosis rates for lower urinary tract symptoms, a move towards utilizing combination therapies, and a broader adoption of home-based strategies for nocturia management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21232&type=smp
Nocturia Market Growth Drivers And Industry Catalysts
Anticipate an upward trajectory for the nocturia market, largely influenced by the escalating incidence of cardiovascular ailments. These conditions encompass a spectrum of heart and blood vessel disorders, such as heart disease, stroke, and hypertension. Contributing factors to the rise in cardiovascular diseases include an aging demographic, inactive lifestyles, suboptimal dietary habits, smoking, excessive alcohol intake, obesity, elevated blood pressure and cholesterol levels, diabetes, and hereditary factors. Nocturia frequently presents as a symptom in individuals with cardiovascular conditions, consequently increasing the demand for diagnostic tools and therapeutic interventions. With the global surge in cardiovascular issues, exacerbated by an aging populace and detrimental lifestyle choices, the imperative for robust nocturia management strategies will intensify. Illustratively, the British Heart Foundation reported in September 2025 that over 7.6 million individuals in the UK, comprising more than 4 million men and over 3.6 million women, are contending with cardiovascular disease, with forecasts suggesting an approximate addition of 1 million cases by 2030 and around 2 million by 2040, primarily due to an aging population and enhanced survival rates. Consequently, the expanding prevalence of cardiovascular diseases is a significant catalyst for the nocturia market’s expansion.
Nocturia Market Categorization By Product Type And Application
The nocturia market covered in this report is segmented –
1) By Drug: Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic, Other Drugs
2) By Indication: Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, Global Polyuria
3) By Causes: Urological Infection, Tumor Of The Bladder, Diuretic Medications, Regular Alcohol Or Coffee, Liver Infection, Diabetes, Pregnancy, Other Causes
4) By End User: Hospitals, Home Care, Clinics
Subsegments:
1) By Anticholinergic Drugs: Oxybutynin, Tolterodine, Solifenacin, Darifenacin, Fesoterodine
2) By Desmopressin: Intranasal Desmopressin, Oral Desmopressin
3) By Antibiotics: Nitrofurantoin, Trimethoprim, Fosfomycin
4) By Antispasmodic: Hyoscine Butylbromide, Flavoxate
5) By Other Drugs: Alpha-Blockers, Beta-3 Agonists
#Nocturia Market Trends Influencing Long-Term Demand
In the realm of the nocturia market, leading enterprises are prioritizing the creation of novel solutions, exemplified by orally disintegrating tablets, to improve patient ease of use and adherence to treatment. These orally disintegrating tablets (ODTs), a type of solid oral formulation, are designed to rapidly break down within the mouth, thus eliminating the need for water and proving particularly beneficial for individuals experiencing difficulties with swallowing. A relevant development occurred in July 2024 when Adalvo Limited, a pharmaceutical entity headquartered in Malta, introduced Desmopressin ODT across Europe. This medication is prescribed for ailments characterized by excessive fluid loss by the body, including central cranial diabetes insipidus. Functioning as a synthetic analog of vasopressin, this tablet effectively manages diabetes insipidus, extreme thirst and urinary frequency, and nocturnal enuresis by replicating the actions of the body’s natural hormone and reducing the volume of water expelled in urine. Furthermore, its therapeutic application extends to managing hemorrhages in cases of mild to moderate hemophilia A and von Willebrand disease through the augmentation of blood-clotting factor release.
Nocturia Market Company Landscape And Strategic Competition
Major companies operating in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc
Access The Complete Nocturia Market Report:
https://www.thebusinessresearchcompany.com/report/nocturia-global-market-report
Nocturia Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the nocturia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the nocturia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model